Allergan receives approval for its migraine drug Ubrelvy from FDA
Category: #health  By Pankaj Singh  Date: 2019-12-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Allergan receives approval for its migraine drug Ubrelvy from FDA

Allergan, a renowned multinational biopharmaceutical company, has been awarded approval for its oral CGRP (calcitonin gene-related peptide) medicine for the treatment of migraines. The field of CGRP migraine prevention already contains three medicines, from Eli Lilly, Amgen and Teva, competing for a chunk of the market share.

The medication, Ubrelvy, previously known as ubrogepant, received FDA approval, becoming the first ever oral CGRP medicine for the treatment of migraines. The company’s medicine is considered to be an effective treatment for migraine without or with aura, referring to the visual or sensory disturbances that usually occur in roughly a third of migraine sufferers.

The med is expected to face competition from rimegepant, developed by Biohaven, by 2020. Allergan is planning to launch the drug by the first quarter (Q1) next year.

Peter Goadsby, neurologist and professor, King’s College, reportedly stated that during clinical trials the medication provided pain relief to a majority of participants as compared to placebo. The drug has also helped give relief from other symptoms like sound and light sensitivity and nausea.

The analysts from EvaluatePharma have made a prediction that by 2024 the drug would likely generate $302 million in revenues.

The field of migraine saw a surge in activity due to three CGRP approvals in last year along with corresponding launches. Although Eli Lilly had lately been gaining steam with its Emgality, Amgen lead the market with its Aimovig medication.

Eli Lilly scored approval from FDA for Emgality to address cluster headaches and for Reyvow, a new migraine treatment. The firm is expecting to launch Reyvow by early 2020 following a DEA scheduling.

Additionally, Allergan will be combining with AbbVie by next year as part of a merger, the two companies will sign the agreement in June.

The American Migraine Foundation stated that an estimate of 40 million Americans and 1 billion people across the world suffer from migraines. It is likely to affect one in five women and one in 16 men.

Source credit: https://www.fiercepharma.com/pharma/allergan-scores-year-end-fda-nod-for-cgrp-migraine-med-ubrelvy-plans-early-2020-launch



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...